RecruitingPhase 3NCT05335876
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
Studying Spinal Muscular Atrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis Pharmaceuticals
- Intervention
- onasemnogene abeparvovec(biological)
- Enrollment
- 175 enrolled
- Eligibility
- 0-100 years · All sexes
- Timeline
- 2022 – 2030
Study locations (18)
- Child Hosp Of The Kings Daughters, Norfolk, Virginia, United States
- Novartis Investigative Site, Sydney, New South Wales, Australia
- Novartis Investigative Site, Leuven, Belgium
- Novartis Investigative Site, Curitiba, Paraná, Brazil
- Novartis Investigative Site, São Paulo, São Paulo, Brazil
- Novartis Investigative Site, Montreal, Quebec, Canada
- Novartis Investigative Site, Chongqing, Chongqing Municipality, China
- Novartis Investigative Site, Guangzhou, Guangdong, China
- Novartis Investigative Site, Chengdu, Sichuan, China
- Novartis Investigative Site, Beijing, China
- Novartis Investigative Site, Copenhagen, Denmark
- Novartis Investigative Site, Bron, France
- Novartis Investigative Site, Garches, France
- Novartis Investigative Site, Strasbourg, France
- Novartis Investigative Site, Toulouse, France
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05335876 on ClinicalTrials.govOther trials for Spinal Muscular Atrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07488338HABIT-ILE + FST in Children With SMA: Preliminary EffectivenessTeachers College, Columbia University
- RECRUITINGNCT07400198Gait and Bone Health in SMAJacqueline Montes
- RECRUITINGPHASE1, PHASE2NCT07070999Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1Gemma Biotherapeutics
- RECRUITINGNANCT07321977Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic VolunteersInstitut de Myologie, France
- RECRUITINGPHASE2NCT07287982A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophyargenx
- RECRUITINGNANCT07286565Active NBS Study: Decentralised Monitoring Motor Development in Children With Duchenne Muscular Dystrophy or Spinal Muscular Atrophy Identified by Newborn ScreeningCentre Hospitalier Universitaire de Liege
- RECRUITINGNCT06532474Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed TherapiesSt. Jude Children's Research Hospital
- RECRUITINGPHASE3NCT07265232Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).Lantu Biopharma